Pulmonary hypertension: diagnostic and therapeutic challenges

Isabel S Bazan, Wassim H Fares Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CT, USA Abstract: Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic state that can be found in multiple conditions with associated sym...

Full description

Bibliographic Details
Main Authors: Bazan IS, Fares WH
Format: Article
Language:English
Published: Dove Medical Press 2015-08-01
Series:Therapeutics and Clinical Risk Management
Online Access:http://www.dovepress.com/pulmonary-hypertension-diagnostic-andnbsptherapeutic-challenges-peer-reviewed-article-TCRM
id doaj-d7d30e4b693c465cae5d135121efaef6
record_format Article
spelling doaj-d7d30e4b693c465cae5d135121efaef62020-11-24T22:49:40ZengDove Medical PressTherapeutics and Clinical Risk Management1178-203X2015-08-012015default1221123323171Pulmonary hypertension: diagnostic and therapeutic challengesBazan ISFares WHIsabel S Bazan, Wassim H Fares Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CT, USA Abstract: Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic state that can be found in multiple conditions with associated symptoms of dyspnea, decreased exercise tolerance, and progression to right heart failure. The World Health Organization has classified PH into five groups. The first group is pulmonary arterial hypertension (PAH), which can be idiopathic, heritable, due to drugs and toxins, or associated with conditions such as connective tissue diseases, congenital heart disease, portal hypertension, and others. The development of PAH is believed to result from smooth muscle cells and endothelial dysfunction that impairs production of vasodilators, including nitric oxide and prostacyclin. The importance of distinguishing this group from the other groups of PH is that there are PAH-specific drugs that target the molecular pathways that are pathogenic in the vascular derangements, leading to arterial hypertension, which should not be used in the other forms of PH. Other groups of PH include PH due to left heart disease, lung disease, chronic thromboembolic disease, as well as a miscellaneous category. Echocardiography is used to screen for PH and has varying sensitivity and specificity in detecting PH. Additionally, the right heart pressures estimated during echocardiogram often differ from those obtained during confirmatory testing with right heart catheterization. The most challenging PH diagnosis is in a case that does not fit one group of PH, but meets criteria that overlap between several groups. This also makes the treatment challenging because each group of PH is managed differently. This review provides an overview of the five groups of PH and discusses the diagnostic and therapeutic challenges of each. Keywords: pulmonary hypertension, pulmonary arterial hypertension, right heart failure, diagnosis, managementhttp://www.dovepress.com/pulmonary-hypertension-diagnostic-andnbsptherapeutic-challenges-peer-reviewed-article-TCRM
collection DOAJ
language English
format Article
sources DOAJ
author Bazan IS
Fares WH
spellingShingle Bazan IS
Fares WH
Pulmonary hypertension: diagnostic and therapeutic challenges
Therapeutics and Clinical Risk Management
author_facet Bazan IS
Fares WH
author_sort Bazan IS
title Pulmonary hypertension: diagnostic and therapeutic challenges
title_short Pulmonary hypertension: diagnostic and therapeutic challenges
title_full Pulmonary hypertension: diagnostic and therapeutic challenges
title_fullStr Pulmonary hypertension: diagnostic and therapeutic challenges
title_full_unstemmed Pulmonary hypertension: diagnostic and therapeutic challenges
title_sort pulmonary hypertension: diagnostic and therapeutic challenges
publisher Dove Medical Press
series Therapeutics and Clinical Risk Management
issn 1178-203X
publishDate 2015-08-01
description Isabel S Bazan, Wassim H Fares Department of Internal Medicine, Section of Pulmonary, Critical Care and Sleep Medicine, Yale University, New Haven, CT, USA Abstract: Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic state that can be found in multiple conditions with associated symptoms of dyspnea, decreased exercise tolerance, and progression to right heart failure. The World Health Organization has classified PH into five groups. The first group is pulmonary arterial hypertension (PAH), which can be idiopathic, heritable, due to drugs and toxins, or associated with conditions such as connective tissue diseases, congenital heart disease, portal hypertension, and others. The development of PAH is believed to result from smooth muscle cells and endothelial dysfunction that impairs production of vasodilators, including nitric oxide and prostacyclin. The importance of distinguishing this group from the other groups of PH is that there are PAH-specific drugs that target the molecular pathways that are pathogenic in the vascular derangements, leading to arterial hypertension, which should not be used in the other forms of PH. Other groups of PH include PH due to left heart disease, lung disease, chronic thromboembolic disease, as well as a miscellaneous category. Echocardiography is used to screen for PH and has varying sensitivity and specificity in detecting PH. Additionally, the right heart pressures estimated during echocardiogram often differ from those obtained during confirmatory testing with right heart catheterization. The most challenging PH diagnosis is in a case that does not fit one group of PH, but meets criteria that overlap between several groups. This also makes the treatment challenging because each group of PH is managed differently. This review provides an overview of the five groups of PH and discusses the diagnostic and therapeutic challenges of each. Keywords: pulmonary hypertension, pulmonary arterial hypertension, right heart failure, diagnosis, management
url http://www.dovepress.com/pulmonary-hypertension-diagnostic-andnbsptherapeutic-challenges-peer-reviewed-article-TCRM
work_keys_str_mv AT bazanis pulmonaryhypertensiondiagnosticandnbsptherapeuticchallenges
AT fareswh pulmonaryhypertensiondiagnosticandnbsptherapeuticchallenges
_version_ 1716460403626606592